About Event
The industry-leading forum focussed on ways to predict, monitor, and mitigate against adverse immune responses to AAV gene therapies.
Successful advancement of gene therapy through clinical trials hinges on the development of robust, clinically validated immunoassays and biodistribution studies. These assays, coupled with real-world data, are instrumental in mitigating efficacy and safety roadblocks that can impede progress and, more critically, jeopardize patient safety.
An in-depth understanding of the of the innate and adaptive immune response, predictable translational models and immunosuppression and modulation strategies to mitigate against adverse responses are vital in developing a safe and effective gene therapy product.
This is your opportunity to tackle gene therapy immunogenicity in the ‘here and now’ across, 3 days of in-depth case studies, deep dive workshops and insightful panel discussions.
Join Your Peers to:
NEW FOR 2024 Immunogenicity Challenges for Gene Editing
Learn about the unique immunogenicity challenges posed by gene editing therapies from CRISPR Therapeutics and Modalis Therapeutics in our brand-new section dedicated to gene editing
Immune Modulation and Suppression
Hear the latest updates in immune mitigation strategies for local and systemic gene therapies with insights form Spark Therapeutics and Solid Biosciences
Immune Responses to the Therapeutic Gene
Hear from Regeneron and Roche on their latest data from studies into cellular immune responses into the transgene product and disease specific approaches to overcoming immune these reactions
Novel Immunoassays, Bioanalytical and Biodistribution technology
Explore freshly validated assays for T cell quantification and AAV biodistribution with talks from Boehringer Ingelheim and Astellas Gene Therapies
AAV Redosing
Look into the future of gene therapies and explore AAV redosing through an immunology lens in a deep-dive workshop with The University of Indiana School of Medicine
Audience Summary
This summit brings together professionals from preclinical, clinical, translational, bioanalytical, toxicology, and pharmacology development to get the latest insights into overcoming immunogenicity bottlenecks in gene therapy development.
R&D – Discover and digest the latest and greatest in ensuring the safety and efficacy of gene therapies to gain actionable insights for your own gene therapy development efforts.
Business Development – Engage with other business leaders from 40+ industry groups to set up collaborations, secure investment, and unlock future company deals
Service Provider – Position yourself as a leading vendor in the gene therapy development field and win business. Check out our partnership opportunities here
Academia – Leverage the latest data and tech developments from the industry into your own research and network with industry leaders in the field
Testimonials
“If you work on AAV immunogenicity, this meeting is the best place for a direct contact and exchange of ideas with the most relevant colleagues in the gene therapy industry.” Klaudia Kuranda, Head of Immunology, Spark Therapeutics